Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
|Slideshows|March 9, 2021
How to Switch Stimulants: A Dosing Guide for ADHD
Author(s)Chris Aiken, MD
Getting the dose just right can be tough...
Advertisement
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement